Paulo Garcia, Ph.D., CEO
Cambridge, MA
Kytopen is a spin-out of MIT developing proprietary platforms for non-viral delivery of payloads for ex vivo cell therapy discovery and manufacturing. The scalable solution combines fluid handling and automation to make transfection easier, faster, and more cost-effective than the state-of-the art solutions. Kytopen is integrating their platforms with commercial automated liquid handling systems for processing small volumes and has developed a large volume platform for therapeutic applications. These non-viral solutions will accelerate the time-to-market of next-generation cell and gene therapies by enabling discovery of therapeutic targets and reducing the cell therapy manufacturing costs. Kytopen recently released a beta version of their large scale manufacturing system and is actively engaging with potential partners.

By using this website you agree to accept our Privacy Policy and Terms & Conditions